Chinook Therapeutics, Inc.
108 articles about Chinook Therapeutics, Inc.
-
Therapeutics to halt the progression of chronic kidney disease are in Phase III trials, and others will enter that stage soon. NDAs could follow as early as 2024 with regulatory determinations in 2025.
-
Chinook Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
11/10/2022
Chinook Therapeutics, Inc. provided a business update and reported financial results for the quarter and nine months ended September 30, 2022.
-
Biopharma's efforts to conquer immunoglobulin A nephropathy were on full display at ASN's Kidney Week as Ionis, Chinook and Vera all reported positive data.
-
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022
11/4/2022
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced two posters on the BION-1301 and CHK-336 programs being presented today at ASN Kidney Week 2022 being held virtually and live in Orlando, Florida.
-
Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022
11/3/2022
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced two posters and three informational posters being presented today at ASN Kidney Week 2022 being held virtually and live in Orlando, Florida.
-
Chinook Therapeutics to Present at Upcoming November 2022 Investor Conferences
11/2/2022
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.
-
Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the American Society of Nephrology (ASN) Kidney Week 2022
10/14/2022
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced nine abstracts to be presented at ASN Kidney Week 2022 from November 3 – 6, 2022 in Orlando, Florida.
-
Chinook Therapeutics to Present at Upcoming September 2022 Investor Conferences
9/1/2022
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences.
-
Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
8/8/2022
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, provided a business update and reported financial results for the quarter and six months ended June 30, 2022.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Aug 04, 2022
8/4/2022
Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase a total of 24,700 shares of common stock with a grant date of July 29, 2022 for one new employee.
-
Chinook Therapeutics to Present at Upcoming Investor Conferences - Aug 02, 2022
8/2/2022
Chinook Therapeutics, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, announced that Chinook management is scheduled to participate in the following upcoming investor conferences.
-
Women of color continue to be trailblazers in the life science industry, proving that they can be just as, if not more, successful than their peers - even if it isn’t always easy.
-
Chinook Therapeutics to Present at the William Blair Biotech Focus Conference 2022
7/5/2022
Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in a fireside chat and 1x1 meetings at the William Blair Biotech Focus Conference 2022.
-
Chinook Therapeutics Receives Orphan Drug Designation from European Commission for BION-1301 for Treatment of Primary IgA Nephropathy (IgAN)
7/5/2022
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN).
-
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering - May 25, 2022
5/25/2022
Chinook Therapeutics, Inc. announced the pricing of its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share.
-
Chinook Therapeutics Announces Proposed Public Offering - May 24, 2022
5/24/2022
Chinook Therapeutics, Inc. announced that it has commenced an underwritten public offering of its common stock, and, in lieu of common stock, to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock.
-
Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022
5/20/2022
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced two oral presentations on the atrasentan clinical program and Evotec collaboration at the 59th ERA Congress 2022 being held virtually and live in Paris, France.
-
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022
5/19/2022
Chinook Therapeutics, Inc. announced three mini-oral presentations on the BION-1301 and atrasentan clinical programs at the 59th ERA Congress 2022 being held virtually and live in Paris, France.
-
Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
5/12/2022
Chinook Therapeutics, Inc. provided a business update and reported financial results for the first quarter ended March 31, 2022.
-
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 12, 2022
5/12/2022
Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase 45,000 shares of common stock with a grant date of May 6, 2022 to one new employee.